Granulocyte colony-stimulating factor for hepatitis C therapy-associated neutropenia: Systematic review and economic evaluation

Journal of Viral Hepatitis

Volumn 18, Issue 7, 2011, Pages

  Tandon, P ^a   Doucette, K ^a   Fassbender, K ^a   Vandermeer, B ^a   Durec, T ^a   Dryden, D M ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

adverse events; cost effectiveness; granulocyte colony stimulating factor; hepatitis C virus; sustained virologic response

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; PEGASYS RBV; PEGINTERFERON; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RIBAVIRIN; UNCLASSIFIED DRUG;

ANTIBIOTIC THERAPY; BONE PAIN; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; HEPATITIS C; HUMAN; INFECTION; LIVER TRANSPLANTATION; NEUTROPENIA; NEUTROPHIL COUNT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SPLENOMEGALY; SYSTEMATIC REVIEW; TREATMENT DURATION; VIRUS LOAD;

ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; DRUG THERAPY, COMBINATION; GRANULOCYTE COLONY-STIMULATING FACTOR; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON-ALPHA; NEUTROPENIA; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; TREATMENT OUTCOME;

EID: 79959608336     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2011.01445.x     Document Type: Review

References (60)

1. Remis RS,. A Study to Characterize the Epidemiology of Hepatitis C Infection in Canada, 2002. Final Report. Ottawa: Health Canada, 2004.
2. Rehermann B,. Immunopathogenesis of hepatitis C. In: Liang TH, moderator. Pathogensis, natural history, treatment, and prevention of heptitis C. Ann Intern Med 2000; 132: 297-299.
3. Poynard T, Bedossa P,. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997; 349 (9055): 825-832. (Pubitemid 27129209)
4. Wong T, Lee SS,. Hepatitis C: a review for primary care physicians. CMAJ 2006; 174 (5): 649-659. (Pubitemid 43341876)
5. Hong Z, Smart G, Dawood M, et al. Hepatitis C infection and survivals of liver transplant patients in Canada 1997-2003. Transplant Proc 2008; 40: 1466-1470. (Pubitemid 351853142)
6. Sangiovanni A, Prati GM, Fasani P, et al. The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. Hepatology 2006; 43: 1303-1310. (Pubitemid 43980109)
7. Sherman M, Shafran S, Burak K, et al. Management of chronic hepatitis C: consensus guidelines. Can J Gastroenterol 2007; 21 (Suppl C): 25C-34C. (Pubitemid 47177083)
8. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358 (9286): 958-965. (Pubitemid 32913521)
9. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347 (13): 975-982.
10. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140 (5): 346-355.
11. Desmond CP, Roberts SK, Dudley F, et al. Sustained virological response rates and durability of the response to interferon-based therapies in hepatitis C patients treated in the clinical setting. J Viral Hepat 2006; 13 (5): 311-315.
12. Gaeta GB, Precone DF, Felaco FM, et al. Premature discontinuation of interferon plus ribavirin for adverse effects: a multicentre survey in 'real world' patients with chronic hepatitis C. Aliment Pharmacol Ther 2002; 16 (9): 1633-1639.
13. Afdhal NH, Dieterich DT, Pockros PJ, et al. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology 2004; 126 (5): 1302-1311. (Pubitemid 38552795)
14. Russo MW, Ghalib R, Sigal S, Joshi V,. Randomized trial of pegylated interferon alpha-2b monotherapy in haemodialysis patients with chronic hepatitis C. Nephrol Dial Transplant 2006; 21 (2): 437-443. (Pubitemid 43160000)
15. Bain VG, Kaita KD, Yoshida EM, et al. A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients. J Hepatol 2006; 44 (4): 671-678.
16. Cooper CL, Al-Bedwawi S, Lee C, Garber G,. Rate of infectious complications during interferon-based therapy for hepatitis C is not related to neutropenia. Clin Infect Dis 2006; 42 (12): 1674-1678. (Pubitemid 43839429)
17. Dar Santos AE, Partovi N, Ford JA, Yoshida EM,. Use of hematopoietic growth factors as adjuvant therapy for anemia and neutropenia in the treatment of hepatitis C. Ann Pharmacother 2007; 41 (2): 268-275. (Pubitemid 46340057)
18. Dryden DM, Fassbender K, Doucette K, et al. Granulocyte-Colony Stimulating Factor for Antiviral-Associated Neutropenia: Systematic Review and Economic Evaluation. Ottawa: Canadian Agency for Drugs and Technologies in Health, 2008.
19. Jadad AR, Moore A, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary. Control Clin Trials 1996; 17 (1): 1-12. (Pubitemid 26120810)
20. Schulz KF, Chalmers I, Hayes RJ, Altman DG,. Empirical evidence of Bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995; 273 (5): 408-412.
21. Schulz KF, Grimes DA,. Allocation concealment in randomised trials: defending against deciphering. Lancet 2002; 359: 614-618. (Pubitemid 34178448)
22. Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. [Website] 2008 [cited 2008 Jul 18]. Available at:.
23. Egger M, Davey Smith G, Altman DG, eds. Systematic Reviews in Health Care: Meta-Analysis in Context. London: BMJ Publishing Group, 2001.
24. Ball LM, Sulkowski MS, Wolf L, et al. Filgrastim use for interferon induced neutropenia in patients with hepatitis C. Gastroenterology 1999; 116 (4 Pt 2): A1188.
25. Jeffers LJ, Cassidy W, Howell CD, Hu S, Reddy KR,. Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology 2004; 39 (6): 1702-1708. (Pubitemid 38702672)
26. Juarez-Navarro A, Vera-de-Leon L, Navarro JM, et al. Incidence and severity of infections according to the development of neutropenia during combined therapy with pegylated interferon-alpha2a plus ribavirin in chronic hepatitis C infection. Methods Find Exp Clin Pharmacol 2005; 27 (5): 317-322. (Pubitemid 41044273)
27. Koirala J, Gandotra SD, Rao S, et al. Granulocyte colony-stimulating factor dosing in pegylated interferon alpha-induced neutropenia and its impact on outcome of anti-HCV therapy. J Viral Hepat 2007; 14 (11): 782-787. (Pubitemid 47561582)
28. Koskinas J, Zacharakis G, Sidiropoulos J, et al. Granulocyte colony stimulating factor in HCV genotype-1 patients who develop Peg-IFN-α2b related severe neutropenia: a preliminary report on treatment, safety and efficacy. J Med Virol 2009; 81: 848-852.
29. Puoti M, Babudieri S, Rezza G, et al. Use of pegylated interferons is associated with an increased incidence of infections during combination treatment of chronic hepatitis C: a side effect of pegylation? Antivir Ther 2004; 9 (4): 627-630. (Pubitemid 39150220)
30. Renou C, Harafa A, Bouabdallah R, et al. Severe neutropenia and post hepatitis C cirrhosis treatment: is interferon dose adaptation necessary at once? [Abstract]. J Hepatol 2002; 26 (Suppl 1): 231.
31. Senkbeil LE, Moss JG, Gaglio PJ, et al. Erythropoietin maintains ribavirin dose and sustained virologic response during HCV treatment. Hepatology 2003; 38 (4 Suppl 1): 744A.
32. Sharvadze L, Gochitashvili N, Tophuria A, Bolokadze N, Tsertsvadze T,. IFN/RBV treatment induced neutropenia and its correction with neupogen in patients with hepatitis C. Georgian Med News 2007; 147: 52-55.
33. Sood A, Reddy N, Russo MW, Brown RS, Jacobson IM,. Use of granulocyte colony stimulating factor (GCSF) for interferon induced neutropenia in patients with chronic hepatitis C infection. Hepatology 2001; 34 (4 Pt 2): 429A.
34. Soza A, Everhart JE, Ghany MG, et al. Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology 2002; 36 (5): 1273-1279. (Pubitemid 35253446)
35. Tarantino L, De Rosa A, Tambaro O, et al. Lenograstim in the treatment of severe neutropenia in patients treated with Peg-IFN and ribavirin: the experience of a single hepatology unit. Infez Med 2009; 17 (1): 20-23.
36. Yang J-F, Hsieh M-Y, Hou N-J, et al. Bacterial infection and neutropenia during peginterferon plus ribavirin combination therapy in patients with chronic hepatitis C with and without baseline neutropenia in clinical practice. Aliment Pharmacol Ther 2009; 29: 1000-1010.
37. Younossi ZM, Nader FH, Bai C, et al. A phase II dose finding study of darbepoetin alpha and filgrastim for the management of anaemia and neutropenia in chronic hepatitis C treatment. J Viral Hepat 2008; 15: 370-378. (Pubitemid 351473630)
38. Gopal DV, Rabkin JM, Berk BS, et al. Treatment of progressive hepatitis C recurrence after liver transplantation with combination interferon plus ribavirin. Liver Transpl 2001; 7 (3): 181-190. (Pubitemid 32243812)
39. Iacob S, Gheorghe L, Hrehoret D, et al. Pegylated interferon α-2a and ribavirin combination therapy in HCV liver transplant recipients. Experience of 7 cases. J Gastrointestin Liver Dis 2008; 17 (2): 165-172. (Pubitemid 351930762)
40. Neumann U, Puhl G, Bahra M, et al. Treatment of patients with recurrent hepatitis C after liver transplantation with peginterferon alfa-2B plus ribavirin. Transplantation 2006; 82 (1): 43-47. (Pubitemid 44296976)
41. Sharma S, Marrer JA, Fontana RJ, et al. Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence [Abstract]. Liver Transpl 2007; 13: 1100-1108. (Pubitemid 47305028)
42. Howell CD, Jeffers LS, Cassidy W, et al. Peginterferon alfa-2a and ribavirin for chronic hepatitis C genotype 1 infections in black patients: safety, tolerability and impact on sustained virologic response. J Viral Hepat 2006; 13 (6): 371-376. (Pubitemid 44030258)
43. Koskinas J, Zacharakis GH, Sidiropoulos J, et al. G-CSF is safe and improves adherence and SVR in HCV patients with genotype-1 who develop PEG-IFN-2b related severe neutropenia. A mutlicenter study [Abstract]. J Hepatol 2006; 44 (Suppl 2): S200.
44. Puoti M, Antonini MG, Babudieri S, et al. Occurrence of infections during combination treatment with interferons and ribavirin for chronic hepatitis C: role of neutropenia and of interferon pegylation. Hepatology 2003; 38 (4 Suppl 1): 644A.
45. Renou C, Harafa A, Cummins C, et al. Threshold for neutropenia in the adjustment of interferon treatment in HCV infection. Hepatology 2003; 37 (4): 949-950. (Pubitemid 36397410)
46. Renou C, Harafa A, Bouabdallah R, et al. Severe neutropenia and post-hepatitis C cirrhosis treatment: is interferon dose adaptation at once necessary? Am J Gastroenterol 2002; 97 (5): 1260-1263. (Pubitemid 34478138)
47. Senkbeil LE, Moss JG, Gaglio PJ, et al. Erythropoietin maintains ribavirin dose and sustained virologic response during HCV treatment [Abstract]. Hepatology 2003; 38 (Suppl 4): 744A.
48. Canadian Agency for Drugs and Technologies in Health. Guidelines for the Economic Evaluation of Health Technologies: Canada, 3rd edn. Ottawa: Canadian Agency for Drugs and Technologies in Health, 2006.
49. Chapko MK, Dominitz JA,. Cost-effectiveness of growth factors during hepatitis C anti-viral therapy. Aliment Pharmacol Ther 2006; 24 (7): 1067-1077. (Pubitemid 44386532)
50. Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ,. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA 2003; 290: 228-237. (Pubitemid 37430062)
51. McKesson Pharmaceutical,. Pharmaclick [Catalogue online]. Montreal: McKesson Canada, 2008.
52. Carey E, Rosati M, Anderson M, et al. Use of G-CSF allows for optimal PEG-INF dosing during therapy for hepatitis C virus with pegylated interferon and ribavirin. Hepatology 2002; 36 (4 Pt 2): 604A.
53. Gotardo DRM, Abdala E, Bonazzi PR, et al. Safety of recurrent hepatitis C treatment after liver transplantation with use of adjuvants [Abstract]. Liver Transpl 2007; 13 (Suppl 1): S152-S153.
54. Deeks JJ,. Systematic Reviews of Evaluations of Diagnostic and Screening Tests. Systematic Reviews in Health Care: Meta-Analysis in Context. London: BMJ Publishing Group, 2001: 248-282.
55. Maddrey WC,. Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients. Semin Liver Dis 1999; 19 (Suppl 1): 65-75.
56. Barge AJ,. A review of the efficacy and tolerability of recombinant haematopoietic growth factors in bone marrow transplant. Bone Marrow Transplant 1993; 11 (Suppl 2): 1-11. (Pubitemid 23207399)
57. Przepiorka D, Smith TL, Folloder J, et al. Controlled trial of filigrastim for acceleration of neutrophil recovery after allogeneic blood stem cell transplantation from human leukocyte antigen-matched related donors. Blood 2001; 97 (11): 3405-3410.
58. Lamberti JS, Belliner TJ, Schwarzkopf SB, Schneider E,. Filigrastim treatment of three patients with clozapine-induced agranulocytosis. J Clin Psychiatry 1995; 56 (6): 256-259.
59. Marangolo M, Bengala C, Conte PF, et al. Dose and outcome: the hurdle of neutropenia. Oncol Rep 2006; 16 (2): 233-248.
60. Davis GL, Wong JB, McHutchinson JG, et al. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38: 645-652. (Pubitemid 37052151)